Merck (MRK) stock is in focus as its Enflonsia RSV shot is cleared for infants in the U.S. in a market led by Sanofi (SNY) ...

Clesrovimab has been held up by MSD (known as Merck & Co in the US and Canada) as offering simpler dosing and better clinical ...

One day before the potential FDA approval of a rival respiratory syncytial virus (RSV) monoclonal antibody from Merck & Co., ...

Merck's shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus.

The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 ...

Sanofi (NASDAQ:SNY) will begin shipping Beyfortus (nirsevimab) in early Q3 to ensure widespread availability ahead of the ...

Meanwhile, Sanofi has pointed to Beyfortus’ 75% reduction in the incidence of MALRI versus Enflosia’s figure of 60%. The ...

Merck won FDA approval for a shot that protects against RSV, the most common cause of hospitalization among infants ...

Sanofi accelerates global shipping of Beyfortus to prepare healthcare providers months ahead of 2025-2026 RSV season . Paris, June 9, 2025. Sanofi is shipping Beyfortus (nirsevima ...

French drugmaker Sanofi SA (NASDAQ:SNY) on Monday said it is shipping Beyfortus (nirsevimab) starting in early Q3 to ensure ...

It starts with a sniffle. A mild cough. You tell yourself it’s just a cold—babies get those, right? But make no mistake. RSV ...

MRK wins early FDA approval for RSV antibody Enflonsia in infants, with U.S. launch planned before the 2025-26 season.